English
Français
Español
Deutsch
Italiano
Português
Nederlands
Polski
Română
Svenska
Dansk
Suomi
Čeština
Ελληνικά
Magyar
SlovenčinaData temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.
Investlytic score: 1/5 criteria met.
- ❌ Price trend failed
- ⚠️ Mixed growth
- ✅ Debt passed
- ❌ P/E failed
- ❌ Correction failed
Price trend
Overall trend (8 years): insufficient progression (less than x1.5).
Price change 2018 → 2019: -56.44%
Price change 2019 → 2020: 5698.82%
Price change 2020 → 2021: -55.31%
Price change 2021 → 2022: -71.93%
Price change 2022 → 2023: -42.01%
Price change 2023 → 2024: -15.57%
Price change 2024 → 2025: -35.05%
Price change 2025 → 2026: 31.71%
Price change 2026 (year to date): 22.62%
Financial growth
Revenue CAGR (8 years): 5.83%
Earnings CAGR (8 years): N/A
Growth status: positive trend (>1%/yr) in revenue, earnings data insufficient/N/A.
Debt
Debt-to-equity ratio: 0.45
Debt/equity < 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: -1.25
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 42.97% from the high over 6 months.
Excessive correction (> 20.0%).
Criteria of the Investlytic model
- / 5Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| Novacyt S.A. | – | 0.45 | +28.1 % | 🔒 |
| Fermentalg | – | 0.20 | +38.5 % | – |
| Adocia S.A. | – | 5.97 | +18.8 % | – |
| Implanet S.A. | – | 14.66 | +5.0 % | – |
| Valbiotis S.A. | – | 0.73 | +56.9 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|